Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

Next Previous
Trial Profile

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belapectin (Primary)
  • Indications Liver cirrhosis; Non-alcoholic steatohepatitis; Oesophageal varices
  • Focus Registrational; Therapeutic Use
  • Acronyms NASH-RX; NAVIGATE
  • Sponsors Galectin Therapeutics

Most Recent Events

  • 10 Jun 2025 According to a Galectin Therapeutics media release, company will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 highlighting results from this trial
  • 15 May 2025 According to a Galectin Therapeutics media release, company look forward to sharing more biomarker data as it becomes available
  • 12 May 2025 According to a Galectin Therapeutics media release, data from the study were presented at the European Association for the Study of the Liver (EASL) 2025 Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top